The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
| Autor: | Marja-Liisa Karjalainen-Lindsberg, Anne Marie Boesen, Mats Jerkeman, Riikka Räty, Christian H. Geisler, Eva Kimby, Anna Laurell, Grete F. Lauritzsen, Mats Ehinger, Marie Nordström, Erkki Elonen, Christer Sundström, Arne Kolstad, Elisabeth Ralfkiaer, Outi Kuittinen, Jan Delabie, Peter de Nully Brown, Herman Nilsson-Ehle, Mikael Eriksson |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Oncology medicine.medical_specialty Immunology Lymphoma Mantle-Cell Transplantation Autologous Biochemistry Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation International Prognostic Index Risk Factors Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Survival rate Hematology business.industry Cell Biology medicine.disease Chemotherapy regimen 3. Good health Lymphoma Surgery Gene Expression Regulation Neoplastic Survival Rate Transplantation Ki-67 Antigen 030220 oncology & carcinogenesis Female Mantle cell lymphoma business Stem Cell Transplantation 030215 immunology |
| Zdroj: | Blood. 115:1530-1533 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood-2009-08-236570 |
| Popis: | Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|